AJMC September 3, 2024
Ty J. Gluckman, MD, FACC, FAHA, medical director of the Center for Cardiovascular Analytics, Research, and Data Science at Providence St. Joseph Health, explained that the recent CMS announcement of negotiated drug prices under the Inflation Reduction Act (IRA) is promising for reducing the costs of Medicare beneficiaries. However, he expressed concerns about unintentional consequences for future drug innovation.
Also, to ensure that high-risk patients receive effective therapies, Gluckman noted that the health care system must integrate a value-based insurance design, improve education, redesign care delivery, and utilize remote patient monitoring.
This transcript has been lightly edited for clarity.
Transcript
CMS recently announced the negotiated drug prices for the first 10 drugs under the IRA. What is your reaction to...
Today's Sponsors
Today's Sponsor